Cargando…

Combination of EP4 antagonist and checkpoint inhibitors promotes anti-tumor effector T cells in preclinical tumor models

Detalles Bibliográficos
Autores principales:	Bao, Xingfeng, Albu, Diana, Huang, Kuan-Chun, Wu, Jiayi, Twine, Natalie, Nomoto, Kenichi, Woodall-Jappe, Mary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649389/ http://dx.doi.org/10.1186/2051-1426-3-S2-P350

Ejemplares similares

EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity
por: Albu, Diana I., et al.
Publicado: (2017)

Neuropilin-1 drives tumor-specific uptake of chlorotoxin
por: McGonigle, Sharon, et al.
Publicado: (2019)

Targeting regulatory T cells by E7777 enhances CD8 T-cell–mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models
por: Mahdi, Haider S., et al.
Publicado: (2023)

E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling
por: McGonigle, Sharon, et al.
Publicado: (2015)

Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment
por: Yang, Min, et al.
Publicado: (2020)

Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade
por: Bonavita, Eduardo, et al.
Publicado: (2020)

The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015)

Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases
por: Portella, Luigi, et al.
Publicado: (2013)

Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
por: Baba, Yoshifumi, et al.
Publicado: (2020)

Tumor Infiltrating Effector Memory Antigen-Specific CD8(+) T Cells Predict Response to Immune Checkpoint Therapy
por: Principe, Nicola, et al.
Publicado: (2020)

BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy
por: Salmon, Avery J., et al.
Publicado: (2022)

Tailored PGE2 Immunomodulation of moDCs by Nano-Encapsulated EP2/EP4 Antagonists
por: Bödder, Johanna, et al.
Publicado: (2023)

Tumor Purity in Preclinical Mouse Tumor Models
por: Qian, Wubin, et al.
Publicado: (2022)

Lead Optimization Studies of Cinnamic Amide EP2 Antagonists
por: Ganesh, Thota, et al.
Publicado: (2014)

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
por: Sasikumar, Pottayil G., et al.
Publicado: (2021)

SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint
por: Hajaj, Emma, et al.
Publicado: (2020)

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
por: Funahashi, Yasuhiro, et al.
Publicado: (2014)

Combination of EP(4) antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells
por: Wang, Yun, et al.
Publicado: (2021)

A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
por: Mediavilla-Varela, Melanie, et al.
Publicado: (2017)

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE(2)-receptor E-type 4 (EP4), in patients with advanced cancers
por: Hong, David S, et al.
Publicado: (2020)

EpCAM(high) and EpCAM(low) circulating tumor cells in metastatic prostate and breast cancer patients
por: de Wit, Sanne, et al.
Publicado: (2018)

EpCAM(low) Circulating Tumor Cells: Gold in the Waste
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

EpCAM tumor specificity and proteoform patterns in urothelial cancer
por: Dressler, Franz F., et al.
Publicado: (2023)

Poxvirus-based active immunotherapy synergizes with immune checkpoint inhibitors to cause tumor regression and extend survival in preclinical models of cancer
por: Foy, Susan P, et al.
Publicado: (2014)

A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment
por: Farias, A., et al.
Publicado: (2021)

The Borg family of Cdc42 effector proteins Cdc42EP1–5
por: Farrugia, Aaron J., et al.
Publicado: (2016)

Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor
por: Carlson, Noel G, et al.
Publicado: (2009)

Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation
por: Kirkby Shaw, Kristin, et al.
Publicado: (2015)

AB065. EP4 antagonist suppresses bone metastasis in prostate cancer
por: Xu, Song, et al.
Publicado: (2017)

Rapid Maturation of Effector T Cells in Tumors, but Not Lymphoid Organs, during Tumor Regression
por: Norian, Lyse A., et al.
Publicado: (2007)

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy
por: Xu, Shumin, et al.
Publicado: (2023)

The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies
por: Melaiu, Ombretta, et al.
Publicado: (2023)

Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models
por: Canals Hernaez, Diana, et al.
Publicado: (2022)

LIGHTing tumor up for checkpoint blockade
por: Liang, Yong, et al.
Publicado: (2016)

Host Prostaglandin E(2)-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth
por: Amano, Hideki, et al.
Publicado: (2003)

Prostaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer
por: Mizuno, Rei, et al.
Publicado: (2019)

OpenEP: an open-source simulator for electroporation-based tumor treatments
por: Marino, Matías, et al.
Publicado: (2021)

Synthetic promoters to induce immune-effectors into the tumor microenvironment
por: Greenshpan, Yariv, et al.
Publicado: (2021)

Analgesic and anti‐inflammatory properties of novel, selective, and potent EP4 receptor antagonists
por: Chandrasekhar, Srinivasan, et al.
Publicado: (2017)

Involvement of PPARγ in the Anticonvulsant Activity of EP-80317, a Ghrelin Receptor Antagonist
por: Lucchi, Chiara, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fkv679iq02b10or8qqlljdc4gd